Heart & blood pressure · Winter Park, FL
Heart and blood pressure studies in Winter Park, FL
15 recruiting studies have a site in Winter Park.
15 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1Overnight stay mentioned
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
Novartis Pharmaceuticals
- Location
- Winter Park, FL + 4 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Pfizer
- Location
- Winter Park, FL + 27 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Merck Sharp & Dohme LLC
- Location
- Winter Park, FL + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Regeneron Pharmaceuticals
- Location
- Winter Park, FL + 41 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Alnylam Pharmaceuticals
- Location
- Winter Park, FL + 213 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Boehringer Ingelheim
- Location
- Winter Park, FL + 91 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Boehringer Ingelheim
- Location
- Winter Park, FL + 78 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Regeneron Pharmaceuticals
- Location
- Winter Park, FL + 42 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Eli Lilly and Company
- Location
- Winter Park, FL + 12 other US sites
- Eligibility basics
- Ages 45–80
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Regeneron Pharmaceuticals
- Location
- Winter Park, FL + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
CSL Behring
- Location
- Winter Park, FL + 147 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
- Location
- Winter Park, FL + 117 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 1
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Verve Therapeutics, Inc.
- Location
- Winter Park, FL + 9 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Amgen
- Location
- Winter Park, FL + 193 other US sites
- Eligibility basics
- Ages 50–105
- RecruitingPhase 3
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Novo Nordisk A/S
- Location
- Winter Park, FL + 129 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.